EMA Authorised: Docetaxel Kabi (docetaxel) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

The EMA authorised Docetaxel Kabi (docetaxel) from Fresenius Kabi Deutschland GmbH for multiple cancer indications, including head and neck cancer, non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma
• Breast Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Prostate Cancer

Drugs mentioned

• Docetaxel Kabi (docetaxel)

Snippet

Status: Authorised. Therapeutic area: Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Prostatic Neoplasms;Breast Neoplasms. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 04/08/2025